KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Account Payables (2018 - 2025)

Vir Biotechnology's Change in Account Payables history spans 8 years, with the latest figure at $3.0 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 252.63% year-over-year to $3.0 million; the TTM value through Dec 2025 reached $5.0 million, up 605.77%, while the annual FY2025 figure was $5.0 million, 605.77% up from the prior year.
  • Change in Account Payables for Q4 2025 was $3.0 million at Vir Biotechnology, up from -$5.4 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $8.9 million in Q2 2025 and bottomed at -$7.5 million in Q3 2023.
  • The 5-year median for Change in Account Payables is -$99500.0 (2023), against an average of $268350.0.
  • The largest annual shift saw Change in Account Payables plummeted 347.25% in 2021 before it skyrocketed 406.22% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $788000.0 in 2021, then surged by 255.33% to $2.8 million in 2022, then decreased by 6.18% to $2.6 million in 2023, then tumbled by 173.7% to -$1.9 million in 2024, then soared by 252.63% to $3.0 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Change in Account Payables are $3.0 million (Q4 2025), -$5.4 million (Q3 2025), and $8.9 million (Q2 2025).